Sana Biotechnology has bought central nervous system therapy developer and portfolio company Oscine, which is founded on University of Rochester research.
Oscine Therapeutics, a US-based brain disease drug developer spun out of University of Rochester Medical Center, was acquired in September 2020 by cell therapy developer Sana Biotechnology for $8.5m.
Oscine’s cell therapy platform has been developed to treat brain and central nervous system (CNS) diseases including Alzheimer’s and multiple sclerosis. It focuses on leveraging the body’s stem cells to create new glial cells, which typically secure neurons in the brain, after they have been damaged by disease.
Sana…
